Intravesical bacillus Calmette-Guerin treatment for stage T1 grade 3 transitional cell carcinoma of the bladder

Urology

Volumn 52, Issue 5, 1998, Pages 785-789

  Baniel, Jack ^a   Grauss, Doron ^a   Engelstein, Dov ^a   Sella, Avishai ^a  

^a RABIN MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE;

ADULT; AGED; ARTICLE; BLADDER CARCINOMA; CANCER GRADING; CANCER STAGING; FEMALE; FOLLOW UP; HUMAN; INTRAVESICAL DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RECURRENT CANCER; TRANSITIONAL CELL CARCINOMA; TUMOR GROWTH;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRAVESICAL; AGED; AGED, 80 AND OVER; BCG VACCINE; CARCINOMA, TRANSITIONAL CELL; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; RETROSPECTIVE STUDIES; URINARY BLADDER NEOPLASMS;

EID: 0031771059     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(98)00369-0     Document Type: Article

References (27)

1. Cancer Facts and Figures - 1990. 1990;American Cancer Society, Atlanta.
2. Superficial bladder cancer progression and recurrence . J Urol. 130:1983;1083-1086.
3. Jakse G., Loidl W., Seeber G., et al. Stage T1, grade 3 transitional cell carcinoma of the bladder an unfavorable tumor? J Urol. 137:1987;39-43.
4. Morales A., Eidinger D., Bruce A.W. Intracavitary bacillus Calmette-Guérin in the treatment of superficial bladder tumors. J Urol. 116:1976;180-183.
5. Herr H.W., Schwalb D.M., Zhang Z.-F., et al. Intravesical bacillus Calmette-Guérin therapy prevents tumor progression and death from superficial bladder cancer ten-year follow-up of a prospective randomized trial . Clin Oncol. 13:1995;1404-1408.
6. Herr H.W., Wartinger D.D., Fair W.R., et al. Bacillus Calmette-Guérin therapy for superficial bladder cancer a 10-year followup . J Urol. 147:1992;1020-1023.
7. Lamm D.L., Crawford E.D., Blumenstein B., et al. Maintenance BCG immunotherapy of superficial bladder cancer a randomized prospective Southwest Oncology Group study (abstract) . J Urol. 147:1992;274A.
8. Lamm D.L., Blumenstein B.A., Crawford E.D., et al. A randomized trial of intravesical doxorubicin and immunotherapy with bacillus Calmette-Guérin for transitional cell carcinoma of the bladder. N Engl J Med. 325:1991;1205-1209.
9. Matinez-Pineiro J.A., Leon J.J., Martinez-Pineiro L. Jr, et al. Bacillus Calmette-Guérin versus doxorubicin versus thiotepa a randomized prospective study in 202 patients with superficial bladder cancer . J Urol. 143:1990;502-506.
10. Kavoussi L.R., Torrence R.J., Gillen D.P., et al. Results of 6 weekly intravesical bacillus Calmette-Guérin instillations on the treatment of superficial bladder tumors. J Urol. 139:1988;935-940.
11. Dal Bo V., Belmonte P., Veronesi A., et al. Intravesical BCG instillations in patients with carcinoma in situ and pT1 G3 transitional cell carcinoma of the bladder (abstract). Eur Urol. 18:(suppl 1):1990;43.
12. Eure G.R., Cundiff M.R., Schellhammer P.F. Bacillus Calmette-Guérin therapy for high risk stage T1 superficial bladder cancer. J Urol. 147:1992;376-379.
13. Cookson M.S., Sarosdy M.F. Management of stage T1 superficial bladder cancer with intravesical bacillus Calmette-Guérin therapy. J Urol. 148:1992;797-801.
14. Pansadoro V., Emiliozzi P., Defidio L., et al. Bacillus Calmette-Guérin in the treatment of stage T1 grade 3 transitional cell carcinoma of the bladder long-term results . J Urol. 154:1995;2054-2058.
15. Hurle R., Losa A., Ranieri A., et al. Low dose Pasteur bacillus Calmette-Guérin regimen in stage T1, grade 3 bladder cancer therapy. J Urol. 156:1996;1602-1605.
16. Lamm D.L. Long-term results of intravesical treatment for superficial bladder cancer. Urol Clin North Am. 19:1992;573-580.
17. Hudson M.A., Ratliff T.L., Gillen D.P., et al. Single course versus maintenance bacillus Calmette-Guérin therapy for superficial bladder tumors a prospective, randomized trial . J Urol. 138:1987;295-298.
18. Badalament R.A., Herr H.W., Wong G.Y., et al. A prospective randomized trial of maintenance versus non-maintenance intravesical bacillus Calmette-Guérin therapy of superficial bladder cancer. J Clin Oncol. 5:1987;441-449.
19. Bohle A., Gerdes J., Nowe C., et al. Effects of local BCG treatment in patients with bladder cancer on phenotypes and function of mononuclear cells. de Kernion J.B. SIU Reports. 1990;83 Churchill Livingstone, Edinburgh.
20. Siref L.E., Zincke H. Radical cystectomy for historical and pathologic T1, N0, M0 (stage A) transitional cell cancer. Urology. 31:1988;309-311.
21. Stokle M., Alken P., Engelman U., et al. Radical cystectomy - often too late? Eur Urol. 13:1987;361-367.
22. Malkowicz S.B., Nichols P., Lieskovsky G., et al. The role of radical cystectomy in the management of high grade superficial bladder cancer (PA, P1, PIS and P2). J Urol. 144:1990;641-645.
23. Amling C.L., Thrasher J.B., Frazier H.A., et al. Radical cystectomy for stage TA, TIS and T1 transitional cell carcinoma of the bladder. J Urol. 151:1994;31-36.
24. Catalona W.J., Hudson M.A., Gillen D.P., et al. Risks and benefits of repeated courses of intravesical bacillus Calmette-Guérin therapy for superficial bladder cancer. J Urol. 137:1987;220-224.
25. Cookson M.S., Herr H.W., Zhang Z., et al. The treated natural history of high risk superficial bladder cancer 15 years outcome . J Urol. 158:1997;62-67.
26. Thompson R.A., Campbell E.W., Kramer H.C., et al. Late invasive recurrence despite long-term surveillance for superficial bladder cancer. J Urol. 149:1993;1010-1011.
27. Miller E.B., Eure G.R., Schellhammer P.F. Upper tract transitional cell cancer following treatment for superficial bladder cancer with BCG. Urology. 42:1993;26-30.